Psychedelics Aren't Better Than Antidepressants In Treating Depression, Review Concludes

By Dennis Thompson HealthDay ReporterMONDAY, March 23, 2026 (HealthDay News) — Psychedelic drugs don’t appear to work any ...

Dizal’s Phase III NSCLC trial of Zegfrovy meets primary endpoint

The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.
Nasdaq

Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...

Scientists Pump the Brakes on Psychedelic Antidepressant Hype

The hype has been deafening on psychedelics as a promising treatment for depression, sometimes justified, sometimes not.
ascopubs.org

Rationale and study design of the KOV-HIPEC-02R (RECOVER): A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal ...

A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC). This is an ASCO ...
Seeking Alpha

Anavex: Understanding Their Alzheimer's Open-Label Extension Data Skeptically

On Saturday April 5, Anavex announced data from their open-label extension trial, ATTENTION-AD, for early Alzheimer's Disease presented at the AD/PDTM 2025 Conference. ATTENTION-AD is a follow-on ...
ascopubs.org

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial Patients with stage III to IV or recurrent, radiographically ...
Nasdaq

Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych ...

COBENFY was generally well tolerated over 52 weeks with a side effect profile consistent with prior trials of COBENFY in schizophrenia In-trial qualitative interviews found that a majority of ...